10-Q: Skye Bioscience Q3: Nimacimab Combo Shines, Monotherapy Fails

Skye Bioscience's Q3 report reveals mixed Phase 2a results for nimacimab, with monotherapy failing its primary endpoint but combination with semaglutide showing significant weight loss and improved outcomes.

Summary

• Skye Bioscience reported a net loss of $41,482,851 for the nine months ended September 30, 2025, significantly higher than the $16,820,644 loss for the same period in 2024.
• Research and development expenses surged by 183% to $30,892,454 for the nine months ended September 30, 2025, compared to $10,908,538 in the prior year, driven by nimacimab clinical trial and manufacturing costs.
• Cash and cash equivalents decreased substantially to $18,441,079 as of September 30, 2025, from $68,415,741 at December 31, 2024.
• The CBeyond Phase 2a study for nimacimab monotherapy did not meet its primary endpoint for weight loss, showing -1.52% vs. -0.26% for placebo.
• Nimacimab in combination with semaglutide demonstrated clinically meaningful weight loss of -13.2% compared to -10.25% for semaglutide alone (p=0.0372), with no plateau observed through Week 26.
• The combination arm achieved 100% of patients with >5% weight loss and 67% with >10% weight loss, compared to 85% and 50% respectively for semaglutide alone.
• An extension study for nimacimab completed enrollment in September 2025, with data expected in Q1 2026, including a higher 300 mg dose for monotherapy patients.
• The company's estimated legal contingency for the Wendy Cunning lawsuit was reduced to $2,054,357 as of September 30, 2025, following a successful appeal vacating the prior judgment.
• Skye Bioscience believes its current cash and short-term investments of $35,312,308 are sufficient to fund operations for at least 12 months from the report's issuance date (November 10, 2025).

Sentiment

Score: 6

Explanation: The sentiment is mixed. While the monotherapy failure is a significant negative, the strong positive results for the combination therapy with semaglutide provide a clear path forward and substantial market opportunity. The high cash burn and need for future funding are concerns, but the current cash runway is adequate for 12 months, and the legal contingency has been reduced. The overall outlook is cautiously optimistic due to the combination therapy's potential.

Positives

• Nimacimab in combination with semaglutide showed clinically meaningful weight loss (-13.2% vs. -10.25% for semaglutide alone, p=0.0372) in the Phase 2a CBeyond study, with no plateau observed through Week 26.
• The combination therapy achieved superior patient response rates, with 100% of patients achieving greater than 5% weight loss (vs. 85% with semaglutide alone) and 67% achieving greater than 10% weight loss (vs. 50% with semaglutide alone).
• Nimacimab plus semaglutide demonstrated a significant reduction in waist circumference (-11.26cm vs. -8.09cm for semaglutide alone, p=0.0492) and an improved lean mass to fat mass ratio (0.26 vs. 0.13 for semaglutide alone, p=0.0126).
• The combination therapy showed a substantial decrease in rebound weight gain (18.1% vs. 49.8% for semaglutide alone) 12 weeks post-treatment, suggesting sustained benefits.
• Nimacimab 200 mg demonstrated a favorable safety profile with placebo-like tolerability, and no increase in gastrointestinal or neuropsychiatric adverse events when combined with semaglutide.
• The legal contingency estimate for the Wendy Cunning lawsuit was significantly reduced to $2,054,357 following a successful appeal that vacated the prior judgment and remanded the case for a new trial.
• The company's current cash, cash equivalents, and short-term investments of $35,312,308 are projected to fund operations for at least 12 months from the report's issuance date.

Negatives

• Nimacimab monotherapy failed to achieve its primary endpoint of weight loss compared to placebo (-1.52% vs. -0.26%) in the Phase 2a CBeyond study, indicating suboptimal dosing at 200 mg.
• The company reported a significant increase in net loss, more than doubling to $41,482,851 for the nine months ended September 30, 2025, from $16,820,644 in the prior year.
• Research and development expenses increased by 183% to $30,892,454 for the nine months ended September 30, 2025, reflecting a high burn rate for clinical development.
• Cash and cash equivalents decreased sharply from $68,415,741 at December 31, 2024, to $18,441,079 at September 30, 2025, indicating substantial cash utilization.
• Cash used in operating activities more than doubled to $33,296,042 for the nine months ended September 30, 2025, compared to $17,064,377 in the same period of 2024.
• Financing activities provided only $18,158 in cash for the nine months ended September 30, 2025, a drastic reduction from $83,556,563 in the prior year, highlighting reliance on existing capital.
• The accumulated deficit grew to $172,432,523 as of September 30, 2025, reflecting continued operating losses since inception.

Risks

• The company's continued existence is dependent on its ability to raise sufficient additional funding to cover operating expenses and carry out research and development activities.
• There is no guarantee that higher dosing of nimacimab will achieve increased efficacy, and it is possible that higher dosing will produce adversely different safety and tolerability results.
• The company is dependent on third parties for product manufacturing, research, preclinical, and clinical testing, which introduces reliance and potential delays.
• Competitive products or approaches could limit the commercial value of nimacimab, impacting future revenue potential.
• The timing and results of preclinical and clinical trials are uncertain, and the successful development of drug candidates is highly uncertain and costly.
• Macroeconomic factors such as global pandemics, inflation, supply chain issues, government shutdowns, and high interest rates could adversely affect operations and financial position.
• The final amount of loss and loss recoveries in the Wendy Cunning lawsuit remains uncertain, and the estimated amount of potential loss may change in the near term.
• The company's ability to protect its intellectual property is crucial, and risks associated with common stock value exist.

Future Outlook

The company expects to continue incurring significant losses and negative cash flows from operations in the future, requiring additional funding for subsequent nimacimab studies. While current cash is projected to last at least 12 months, the timing and success of future clinical trials for nimacimab, including higher doses and combination therapies, remain uncertain. Data from the Phase 2a extension study is anticipated in Q1 2026, which will include results for a 300 mg nimacimab monotherapy dose. The company also plans to expand its metabolic program with other research and development efforts.

Management Comments

• "In CBeyond, the nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo (-1.52% vs. -0.26% for placebo, mITT). Preliminary pharmacokinetic analysis showed an association between exposure and response, suggesting that the 200 mg, subcutaneous weekly dose was suboptimal as a monotherapy."
• "At the tested dose and exposure levels, nimacimab 200 mg demonstrated a favorable safety profile with placebo-like tolerability. In combination with semaglutide, there was no increase in gastrointestinal (GI) adverse events. Importantly, there were no increases in neuropsychiatric adverse events reported resulting from treatment with nimacimab."
• "In the combination arm, nimacimab 200 mg, subcutaneous weekly dose plus semaglutide demonstrated a clinically meaningful magnitude of weight loss compared to semaglutide alone (-13.2% vs -10.25%, p=0.0372, mITT), with no plateau being observed through Week 26. This finding supports potential further studies to evaluate combinations of nimacimab and incretin-based therapies."
• "We believe multiple factors support evaluation of nimacimab at higher doses, including the combination of preclinical toxicology safety margins and modeling; preclinical pharmacology data showing dose-dependent increases in weight loss with nimacimab monotherapy and GLP-1 combinations; and the notable safety profile in the Phase 2a study."
• "Our current cash will be sufficient to fund its projected operations for at least 12 months from the date of the issuance of these consolidated financial statements."

Industry Context

The obesity treatment market is rapidly expanding, largely driven by the success of incretin-based therapies like semaglutide (Wegovy). Skye Bioscience's nimacimab, a CB1 receptor modulator, aims to offer a differentiated mechanism. While nimacimab monotherapy's failure at the 200 mg dose is a setback, its strong performance in combination with semaglutide positions it as a potential adjunctive therapy. This strategy could allow Skye to tap into the lucrative GLP-1 market by offering enhanced efficacy and potentially mitigating rebound weight gain, a known challenge with GLP-1 monotherapy. The focus on a peripherally restricted mechanism aims to avoid central nervous system side effects seen with earlier CB1 antagonists.

Comparison to Industry Standards

• Nimacimab's monotherapy weight loss of -1.52% at 26 weeks is significantly lower than typical results for leading GLP-1 agonists like semaglutide (Wegovy), which showed approximately 15% weight loss in the STEP-1 trial over 68 weeks.
• In combination with semaglutide, nimacimab achieved -13.2% weight loss compared to -10.25% for semaglutide alone, representing an additional 2.95% weight loss. This incremental benefit is notable when compared to other combination strategies or monotherapies in the obesity space.
• The 100% of patients achieving >5% weight loss and 67% achieving >10% weight loss in the combination arm surpasses the 85% and 50% respectively for semaglutide alone, indicating a higher proportion of responders and greater magnitude of response.
• The observed decrease in rebound weight gain (18.1% vs. 49.8% for semaglutide alone) 12 weeks post-treatment is a significant advantage, addressing a key limitation of current GLP-1 therapies where patients often regain a majority of weight after cessation, as demonstrated in studies like Wilding et al., 2022 (STEP-1 Trial Extension).
• The favorable safety profile of nimacimab, with placebo-like tolerability and no increase in GI or neuropsychiatric adverse events in combination, compares favorably to some historical CB1 antagonists that faced safety challenges, and suggests potential for better patient adherence than therapies with more pronounced side effects.

Corporate Governance

Legal Proceedings

• The company is a party to a legal proceeding, Wendy Cunning vs. Skye Bioscience, Inc., alleging wrongful termination, whistleblower protection violations, and retaliation.
• A jury initially awarded the plaintiff $512,500 in economic damages, $840,960 in non-economic damages, and $3,500,000 in punitive damages on January 18, 2023.
• Attorney fees of $1,200,008 were awarded on August 2, 2023.
• The company successfully appealed the judgment, with the Ninth Circuit vacating the judgment and remanding the case for a new trial on October 22, 2024.
• The appeal bond of $9,080,202, previously posted, was recovered during the year ended December 31, 2024.
• As of September 30, 2025, the estimated legal contingency, including accrued legal expenses, is $2,054,357.
• The new trial is currently scheduled to be held in February 2026, and the final amount of loss and loss recoveries remains uncertain.

Stakeholder Impact

• **Shareholders**: Mixed impact due to monotherapy failure but strong combination therapy results. High R&D expenses and net losses indicate continued dilution risk from future capital raises, but the potential for a successful combination therapy could drive long-term value.
• **Employees**: Increased headcount in R&D and continued stock-based compensation plans (Amended and Restated Plan, Inducement Plan, ESPP) suggest ongoing investment in talent, but cost reduction plans implemented after the nimacimab Phase 2a primary endpoint miss could create uncertainty.
• **Customers (future patients)**: The positive results for nimacimab in combination with semaglutide offer potential for a more effective and sustained weight loss treatment, especially addressing rebound weight gain, which could improve patient outcomes.
• **Creditors**: The company's significant cash burn and reliance on future financing for continued operations present a moderate risk, though the current cash runway of 12+ months provides some stability.
• **Suppliers/Contract Research Organizations (CROs)**: Increased R&D expenses, particularly for clinical trial and manufacturing costs, indicate continued engagement and business for third-party partners, but potential cost reduction plans could impact future contracts.

Next Steps

• Report data from the Phase 2a extension study for nimacimab in Q1 2026.
• Plan for potential future clinical studies for nimacimab, including evaluating higher doses and combinations with incretin-based therapies.
• Secure additional funding to support future clinical studies for nimacimab.
• Continue efforts to expand the metabolic program with other research and development activities.
• Participate in a new trial for the Wendy Cunning lawsuit, currently scheduled for February 2026.

Key Dates

Recommendation

The filing presents a mixed bag of results. The failure of nimacimab monotherapy at the 200 mg dose is a clear negative, indicating a setback for that specific development path. However, the highly positive and statistically significant results of nimacimab in combination with semaglutide are a strong positive, suggesting a viable and potentially superior treatment option in the rapidly growing obesity market, especially given the reduced rebound weight gain. The company's financial position shows a high burn rate and significant losses, necessitating future capital raises, but the current cash runway is stated as sufficient for at least 12 months. The reduction in legal contingency is also favorable. Given the significant potential of the combination therapy balanced against the monotherapy failure and ongoing funding needs, a 'hold' recommendation is appropriate. Investors should await further data from the extension study and clarity on future development plans and financing before making a more definitive move.

Keywords

Skye Bioscience, nimacimab, obesity, overweight, CB1 receptor, Phase 2a clinical trial, semaglutide, GLP-1, weight loss, biotechnology, clinical stage, financial results, SEC filing, 10-Q, drug development, metabolic diseases, CBeyond study